Heron Therapeutics, Inc. is a commercial-stage biotechnology company. Co. commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. We show 50 historical shares outstanding datapoints in our HRTX shares outstanding history coverage, used to compute HRTX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing HRTX market cap history over the course of time is important for investors
interested in comparing HRTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of HRTX versus a peer is one thing; comparing
HRTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like HRTX can fluctuate over the course of history.
With this page we aim to empower investors researching HRTX by allowing them to research the HRTX market cap history. |
Free HRTX Email Alerts:
Video: The Importance of Market Cap
